Exelixis (EXEL) Tops Q1 EPS by 25c, provides guidance
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $50.61 +0.46%
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q1 EPS of $0.62, $0.25 better than the analyst estimate of $0.37. Revenue for the quarter came in at $555.4 million versus the consensus estimate of $495.3 million.
GUIDANCE:
Exelixis sees FY2025 revenue of $2.25-2.35 billion, versus the consensus of $2.252 billion.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
